novo nordisk glp-1 receptor agonist weight management diabetes treatments obesity drugs cleared of suicide warning GLP-1 receptor agonists | How

Obesity is a chronic disease that exacerbates the risk of severe health conditions (as mentioned above) and is the leading cause of all-cause mortality

The first GLP-RA, twice-daily exenatide, was approved in the USA in 2005 [3] and, most recently, semaglutide received approval for administration by injection in 2017 [4] and in an oral formulation in 2019 [5]

GLP-1 meds stimulate insulin production when blood sugar is high, stop the liver from releasing excess sugar and slow stomach emptying to prevent blood sugar spikes after meals

Wegovy craze was all the rage on Q3 earnings calls

[DOI] [PubMed] [Google Scholar] 71

That sounds great, right